Solventum Corp. (SOLV)
91.69
-0.75
(-0.81%)
USD |
NYSE |
Sep 04, 16:00
91.69
0.00 (0.00%)
After-Hours: 20:00
Solventum Research and Development Expense (Quarterly) : 178.00M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 178.00M |
| March 31, 2026 | 186.00M |
| December 31, 2025 | 168.00M |
| September 30, 2025 | 183.00M |
| June 30, 2025 | 184.00M |
| March 31, 2025 | 190.00M |
| December 31, 2024 | 199.00M |
| Date | Value |
|---|---|
| September 30, 2024 | 189.00M |
| June 30, 2024 | 192.00M |
| March 31, 2024 | 195.00M |
| December 31, 2023 | 190.00M |
| September 30, 2023 | 180.00M |
| June 30, 2023 | 193.00M |
| March 31, 2023 | 195.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Stryker Corp. | 424.00M |
| Zimmer Biomet Holdings, Inc. | 104.80M |
| Edwards Lifesciences Corp. | 278.90M |
| Intuitive Surgical, Inc. | 370.40M |
| Inspire Medical Systems, Inc. | 24.70M |